MIRA制药公司Ketamir-2号通过安全测试,定于2025年进行人类试验,以治疗神经病痛。 MIRA Pharmaceuticals' Ketamir-2 passes safety tests, set for human trials in 2025 to treat neuropathic pain.

MIRA制药公司已经证实Ketamir-2的安全性,一种口服氯胺酮模拟物,通过临床前期研究,没有显示出任何不利影响。 MIRA Pharmaceuticals has confirmed the safety of Ketamir-2, an oral ketamine analog, through preclinical studies, showing no adverse effects. 这一成功使公司能够为2025年初开始的人类试验作准备,重点是治疗神经病痛。 This success allows the company to prepare for human trials starting in early 2025, focusing on treating neuropathic pain. 积极的安全状况增加了监管批准和临床成功结果的可能性。 The positive safety profile increases the likelihood of regulatory approval and successful clinical outcomes.